Patents Assigned to DFB Pharmaceuticals, Inc.
  • Patent number: 7700351
    Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.
    Type: Grant
    Filed: October 21, 2008
    Date of Patent: April 20, 2010
    Assignee: DFB Pharmaceuticals, Inc.
    Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
  • Publication number: 20100068281
    Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.
    Type: Application
    Filed: September 18, 2009
    Publication date: March 18, 2010
    Applicant: DFB PHARMACEUTICALS, INC.
    Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
  • Publication number: 20090257986
    Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.
    Type: Application
    Filed: January 14, 2009
    Publication date: October 15, 2009
    Applicant: DFB Pharmaceuticals, Inc.
    Inventors: Thomas Hunziker, Alain Limat
  • Publication number: 20090232791
    Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.
    Type: Application
    Filed: October 21, 2008
    Publication date: September 17, 2009
    Applicant: DFB PHARMACEUTICALS, INC.
    Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
  • Patent number: 7449333
    Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: November 11, 2008
    Assignee: DFB Pharmaceuticals, Inc.
    Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
  • Publication number: 20060292126
    Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.
    Type: Application
    Filed: October 31, 2005
    Publication date: December 28, 2006
    Applicant: DFB Pharmaceuticals, Inc.
    Inventors: Thomas Hunziker, Alain Limat
  • Patent number: 7144729
    Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: December 5, 2006
    Assignee: DFB Pharmaceuticals, Inc.
    Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
  • Publication number: 20060240555
    Abstract: The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting same. The reconstituted tissue is particularly suitable for use as a skin graft.
    Type: Application
    Filed: February 24, 2006
    Publication date: October 26, 2006
    Applicant: DFB Pharmaceuticals, Inc.
    Inventor: Vincent Ronfard
  • Publication number: 20060134093
    Abstract: The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting same. The reconstituted tissue is particularly suitable for use as a skin graft.
    Type: Application
    Filed: September 5, 2003
    Publication date: June 22, 2006
    Applicant: DFB Pharmaceuticals, Inc.
    Inventor: Vincent Ronfard
  • Patent number: 7014849
    Abstract: The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: March 21, 2006
    Assignee: DFB Pharmaceuticals, Inc.
    Inventors: Thomas Hunziker, Alain Limat